CN102333863A - 非胚胎干细胞及其用途 - Google Patents

非胚胎干细胞及其用途 Download PDF

Info

Publication number
CN102333863A
CN102333863A CN2010800045093A CN201080004509A CN102333863A CN 102333863 A CN102333863 A CN 102333863A CN 2010800045093 A CN2010800045093 A CN 2010800045093A CN 201080004509 A CN201080004509 A CN 201080004509A CN 102333863 A CN102333863 A CN 102333863A
Authority
CN
China
Prior art keywords
cell
cells
compsn
blscs
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800045093A
Other languages
English (en)
Chinese (zh)
Inventor
詹姆斯·王
阎云
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stembios Technologies Inc
Original Assignee
Stembios Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stembios Technologies Inc filed Critical Stembios Technologies Inc
Publication of CN102333863A publication Critical patent/CN102333863A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90203—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gynecology & Obstetrics (AREA)
CN2010800045093A 2009-01-13 2010-01-13 非胚胎干细胞及其用途 Pending CN102333863A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14420609P 2009-01-13 2009-01-13
US61/144,206 2009-01-13
PCT/US2010/020884 WO2010083203A2 (en) 2009-01-13 2010-01-13 Non-embryonic stem cells and uses thereof

Publications (1)

Publication Number Publication Date
CN102333863A true CN102333863A (zh) 2012-01-25

Family

ID=42337124

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800045093A Pending CN102333863A (zh) 2009-01-13 2010-01-13 非胚胎干细胞及其用途

Country Status (6)

Country Link
US (1) US8394630B2 (enExample)
EP (1) EP2387609B1 (enExample)
JP (1) JP5711149B2 (enExample)
CN (1) CN102333863A (enExample)
ES (1) ES2675553T3 (enExample)
WO (1) WO2010083203A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023025302A1 (zh) * 2021-08-26 2023-03-02 清华大学 诱导全能性干细胞及其制备方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563307B2 (en) * 2009-02-24 2013-10-22 James Wang Treatment of immunosuppression-related disorders
US8679474B2 (en) 2010-08-04 2014-03-25 StemBios Technologies, Inc. Somatic stem cells
US9422526B2 (en) 2011-06-14 2016-08-23 The University Of North Carolina At Chapel Hill Isolation, expansion and use of autologous pluripotent stem cells
TWI614340B (zh) 2011-09-28 2018-02-11 幹細胞生物科技股份有限公司 體幹細胞及其製備方法
TWI687519B (zh) 2012-12-06 2020-03-11 美商幹細胞生物科技股份有限公司 Ｌｇｒ５＋體幹細胞
EP2746769A1 (en) 2012-12-21 2014-06-25 Stembios Technologies, Inc. Method for evaluating effect of action on subject based on stem celldynamics
WO2014143383A1 (en) 2013-03-13 2014-09-18 Agilent Technologies, Inc. Transposome tethered to a gene delivery vehicle
EP3220929A4 (en) * 2014-11-19 2018-06-27 Stembios Technologies, Inc. Somatic stem cells for treating bone defects
DK3364997T5 (da) 2015-10-22 2024-09-30 Univ Massachusetts Aspartoacylase genterapi til behandling af canavans sygdom
US11413356B2 (en) 2016-04-15 2022-08-16 University Of Massachusetts Methods and compositions for treating metabolic imbalance

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007100845A2 (en) * 2006-02-27 2007-09-07 Moraga Biotechnology Corporation Non-embryonic totipotent blastomere-like stem cells and methods therefor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6916654B1 (en) 1992-06-29 2005-07-12 Oklahoma Medical Research Foundation Universal donor cells
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5591625A (en) 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
US5908779A (en) 1993-12-01 1999-06-01 University Of Connecticut Targeted RNA degradation using nuclear antisense RNA
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
WO1998042838A1 (en) 1997-03-25 1998-10-01 Morphogenesis, Inc. Universal stem cells
US20030161817A1 (en) * 2001-03-28 2003-08-28 Young Henry E. Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
AU2002241758A1 (en) 2000-10-26 2002-06-18 University Of Florida Drug screening system
AU2002247875B2 (en) 2000-11-27 2007-09-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Transfection of human embryonic stem cells
JP3977136B2 (ja) * 2001-05-22 2007-09-19 キヤノン株式会社 コイルユニット
US7422736B2 (en) 2002-07-26 2008-09-09 Food Industry Research And Development Institute Somatic pluripotent cells
AU2003287429A1 (en) 2002-11-01 2004-06-07 Five Prime Therapeutics, Inc. Stem cell libraries
ATE510006T1 (de) * 2004-09-03 2011-06-15 Moraga Biotechnology Inc Blastomerenähnliche, nichtembryonale, totipotente stammzellen und methoden zur gewinnung und anwendung
EP2410043A3 (en) 2004-12-29 2013-01-23 Hadasit Medical Research Services And Development Ltd. Stem cells culture systems
US8476070B2 (en) 2005-08-29 2013-07-02 Technion Research & Development Foundation Limited Media for culturing stem cells
US20080305079A1 (en) 2006-01-06 2008-12-11 Mount Sinai School Of Medicine Of New York University Myeloid Suppressor Cells, Methods For Preparing Them, and Methods For Using Them For Treating Autoimmunity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007100845A2 (en) * 2006-02-27 2007-09-07 Moraga Biotechnology Corporation Non-embryonic totipotent blastomere-like stem cells and methods therefor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HENRY E. YOUNG ET AL: "Adult-derived stem cells and their potential for use in tissue repair and molecular medicine", 《CELLULAR & MOLECULAR MEDICINE》 *
N.L.HENSON ET AL: "Karyotypic analysis of adult pluripotent stem cells", 《HISTOL HISTOPATHOL》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023025302A1 (zh) * 2021-08-26 2023-03-02 清华大学 诱导全能性干细胞及其制备方法

Also Published As

Publication number Publication date
WO2010083203A2 (en) 2010-07-22
US8394630B2 (en) 2013-03-12
EP2387609B1 (en) 2018-05-16
JP5711149B2 (ja) 2015-04-30
WO2010083203A3 (en) 2010-11-25
ES2675553T3 (es) 2018-07-11
JP2012514983A (ja) 2012-07-05
EP2387609A4 (en) 2013-12-25
EP2387609A2 (en) 2011-11-23
US20100183570A1 (en) 2010-07-22

Similar Documents

Publication Publication Date Title
US11492592B2 (en) Lgr5+ somatic stem cells
US8394630B2 (en) Producing a mammalian pluripotent cell population from mammalian blastomere-like stem cells (BLSCs)
US8623642B2 (en) Somatic stem cells
US20210113624A1 (en) Somatic stem cells
TWI493037B (zh) Sbr及sbt非胚胎幹細胞及製備與使用該細胞之方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20120125